Single Technology Appraisal

Erenumab for preventing migraine [ID1188] 

NICE has received one appeal against the Final Appraisal Determination on the above technology from the following organisations:

  • Joint appellant - British Association for the Study of Headache and Association of British Neurologists

The appeal panel will convene on Wednesday 4 December 2019 at NICE Manchester Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT to hear oral representations from the appellants.

Members of the public, including consultees and commentators for this appraisal, and the press, may request to attend the hearing. The number of places for observers is constrained by the venue, and priority will be given to members of the public who are not employed by the appellant. There are twenty-five places available for this appeal hearing.

Where possible, requests to attend should be made using the form that will be available on the Institute’s web site .This form will be available from 24 October 2019 only. The web site registration will allow requests to attend to be granted on a first-come, first-served basis. The registration period for this appeal will end at midnight on 7 November 2019. Further details relating to public attendance at this appeal are available on the same webpage as above.

A limited number of places at the appeal hearing will be reserved for members of the public who do not have access to the internet. These places should be applied for in writing, addressed to the Appeals Coordinator, to arrive before midnight on 7 November 2019.  Written requests to attend will also be granted on a first-come, first-served basis.